Monday, March 23, 2026
In Detail Full day, Monday, March 23, 2026, Timezone: America/Chicago
12 Senate Democrats Unveil Plan to Cut Costs, Expand Coverage
Marissa Plescia / medcitynews - In a recent letter, Senate Democrats proposed lowering healthcare costs, expanding coverage and cracking down on insurance company practices.The post 12 Senate Democrats Unveil Plan to Cut Costs, Expand Coverage appeared first on MedCity News.
AI Summary: A group of Senate Democrats released a package targeting insurance costs and access, proposing steps to lower premiums, expand coverage pathways and increase oversight of insurers. The agenda signals a coordinated legislative push to tackle affordability and industry practices, setting the stage for heated negotiations with stakeholders who enjoy the current status quo.
- Medicaid enrollment threatened by work requirements and redeterminations (5)
- Other health policy, market and access stories (9)
- PBMs, insulin pricing face bipartisan and regulatory pressure (6)
- Senate Democrats push reforms to curb insurer power (4)
- All Other Stories
Medicaid enrollment threatened by work requirements and redeterminations
Other health policy, market and access stories
PBMs, insulin pricing face bipartisan and regulatory pressure
Senate Democrats push reforms to curb insurer power
All Other Stories
Pfizer Lyme vaccine candidate heads to FDA
Ella Jeffries / beckershospitalreview - Pfizer and Valneva’s investigational Lyme disease vaccine candidate, PF-07307405 (LB6V), demonstrated more than 70% efficacy in preventing Lyme disease among individuals age 5 and older, according to topline phase 3 trial results. The prespecified analysi…
AI Summary: Pfizer is advancing a Lyme disease vaccine toward FDA submission despite a messy late‑stage picture: efficacy signals above 70% were reported while a pivotal trial missed its primary endpoint and struggled with low case numbers. Regulators must weigh public health need against statistical nuance as the company pushes for licensure.
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Ayisha Sharma / endpoints - Novartis has budgeted $2 billion upfront to buy a more selective PI3Kα inhibitor for breast cancer. The Swiss pharma already has Piqray with a similar target, but drugmakers are now entering the next-generation era as ...
AI Summary: Novartis agreed to pay $2 billion upfront to acquire Synnovation’s mutant‑selective PI3Kα inhibitor, a bet to revive and strengthen PI3K‑targeting combination strategies in breast cancer. The deal swaps in external innovation for internal development speed, shoring up the company’s oncology pipeline while quietly admitting buying is sometimes faster than building.
Innovative research captures emotional and social realities of denture wearers
medicalxpress - Researchers at the University of Sheffield have developed a new patient-focused tool designed to better understand the lived experience of people wearing removable partial dentures. In their study published in the journal Gerodontology, the researchers in…
AI Summary: An international ACT for Children delegation visited Yerevan to support Armenia’s pediatric oncology services through training, resource sharing, and collaborative program development. The visit focused on strengthening local clinical capacity, improving access to treatments, and forging partnerships to advance childhood cancer care—practical help rather than platitudes, with an eye on sustainable improvements.
- Global systems and communication: policy, partnerships, and cultural context (3)
- OTHER: Unrelated health research (denture study) (1)
- Survivorship care: long-term needs, nursing, and AI solutions (3)
- Yerevan visit: ACT for Children strengthens local pediatric oncology care (3)
- All Other Stories
Global systems and communication: policy, partnerships, and cultural context
OTHER: Unrelated health research (denture study)
Survivorship care: long-term needs, nursing, and AI solutions
Yerevan visit: ACT for Children strengthens local pediatric oncology care
All Other Stories
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Oncology, Cancer Screening, Medicare Advantage (not listed), Vitamin D and look for the RSS link.
StackHealth Time Machine
More StackHealth